Use of olopatadine ophthalmic solution and reactivity of histamine skin testing

Jeremy D. Jones, Viviana M. Temino, Ryszard Dworski, Cindy K. Anderson, John M. Fahrenholz, Gel Qi An

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The significant morbidity of allergic rhinitis and allergic conjunctivitis necessitates that diagnosis must be as accurate as possible. However, the very drugs used to treat allergic symptoms have been found to suppress histamine-induced skin testing, making the diagnosis very challenging. Oral formulations of antihistamines are well known to diminish skin test reactivity, but ocular application has never been studied to our knowledge. This study was performed to evaluate whether olopatadine hydrochloride 0.2% ophthalmic solution suppressed histamine-induced wheals and flares on skin-prick testing. A randomized, double-blinded, placebo-controlled, single-center, cross-over pilot study was performed that compared histamine-induced wheal and flare areas after 7-10 days of treatment with both olopatadine 0.2% ophthalmic solution and artificial tears, allowing for a 7- to 10-day washout period between medications. From a total of 24 patients randomized, 21 subjects completed the study, 86% of whom were female. There were no statistically significant differences among both the wheal and the flare areas when comparing treatment with olopatadine and placebo, under the 5% significance level. Although characterized by a small sample size and a preponderance of female subjects, our data suggest that olopatadine does not suppress wheal and flare areas during allergy testing, and discontinuation in preparation for skin-prick testing does not appear to be necessary.

Original languageEnglish
Pages (from-to)636-639
Number of pages4
JournalAllergy and Asthma Proceedings
Volume29
Issue number6
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Ophthalmic Solutions
Histamine
Skin
Placebos
Allergic Conjunctivitis
Histamine Antagonists
Skin Tests
Sample Size
Cross-Over Studies
Hypersensitivity
Morbidity
Olopatadine Hydrochloride
Therapeutics
Pharmaceutical Preparations

Keywords

  • Allergic rhinitis
  • Allergy
  • Azelastine
  • Conjunctivitis
  • Flare
  • Histamine
  • Olopatadine
  • Skin prick
  • Skin testing
  • Wheal

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Jones, J. D., Temino, V. M., Dworski, R., Anderson, C. K., Fahrenholz, J. M., & An, G. Q. (2008). Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. Allergy and Asthma Proceedings, 29(6), 636-639. https://doi.org/10.2500/aap.2008.29.3173

Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. / Jones, Jeremy D.; Temino, Viviana M.; Dworski, Ryszard; Anderson, Cindy K.; Fahrenholz, John M.; An, Gel Qi.

In: Allergy and Asthma Proceedings, Vol. 29, No. 6, 01.11.2008, p. 636-639.

Research output: Contribution to journalArticle

Jones, JD, Temino, VM, Dworski, R, Anderson, CK, Fahrenholz, JM & An, GQ 2008, 'Use of olopatadine ophthalmic solution and reactivity of histamine skin testing', Allergy and Asthma Proceedings, vol. 29, no. 6, pp. 636-639. https://doi.org/10.2500/aap.2008.29.3173
Jones, Jeremy D. ; Temino, Viviana M. ; Dworski, Ryszard ; Anderson, Cindy K. ; Fahrenholz, John M. ; An, Gel Qi. / Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. In: Allergy and Asthma Proceedings. 2008 ; Vol. 29, No. 6. pp. 636-639.
@article{1457504132854b899d8cdc5439c67441,
title = "Use of olopatadine ophthalmic solution and reactivity of histamine skin testing",
abstract = "The significant morbidity of allergic rhinitis and allergic conjunctivitis necessitates that diagnosis must be as accurate as possible. However, the very drugs used to treat allergic symptoms have been found to suppress histamine-induced skin testing, making the diagnosis very challenging. Oral formulations of antihistamines are well known to diminish skin test reactivity, but ocular application has never been studied to our knowledge. This study was performed to evaluate whether olopatadine hydrochloride 0.2{\%} ophthalmic solution suppressed histamine-induced wheals and flares on skin-prick testing. A randomized, double-blinded, placebo-controlled, single-center, cross-over pilot study was performed that compared histamine-induced wheal and flare areas after 7-10 days of treatment with both olopatadine 0.2{\%} ophthalmic solution and artificial tears, allowing for a 7- to 10-day washout period between medications. From a total of 24 patients randomized, 21 subjects completed the study, 86{\%} of whom were female. There were no statistically significant differences among both the wheal and the flare areas when comparing treatment with olopatadine and placebo, under the 5{\%} significance level. Although characterized by a small sample size and a preponderance of female subjects, our data suggest that olopatadine does not suppress wheal and flare areas during allergy testing, and discontinuation in preparation for skin-prick testing does not appear to be necessary.",
keywords = "Allergic rhinitis, Allergy, Azelastine, Conjunctivitis, Flare, Histamine, Olopatadine, Skin prick, Skin testing, Wheal",
author = "Jones, {Jeremy D.} and Temino, {Viviana M.} and Ryszard Dworski and Anderson, {Cindy K.} and Fahrenholz, {John M.} and An, {Gel Qi}",
year = "2008",
month = "11",
day = "1",
doi = "10.2500/aap.2008.29.3173",
language = "English",
volume = "29",
pages = "636--639",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Use of olopatadine ophthalmic solution and reactivity of histamine skin testing

AU - Jones, Jeremy D.

AU - Temino, Viviana M.

AU - Dworski, Ryszard

AU - Anderson, Cindy K.

AU - Fahrenholz, John M.

AU - An, Gel Qi

PY - 2008/11/1

Y1 - 2008/11/1

N2 - The significant morbidity of allergic rhinitis and allergic conjunctivitis necessitates that diagnosis must be as accurate as possible. However, the very drugs used to treat allergic symptoms have been found to suppress histamine-induced skin testing, making the diagnosis very challenging. Oral formulations of antihistamines are well known to diminish skin test reactivity, but ocular application has never been studied to our knowledge. This study was performed to evaluate whether olopatadine hydrochloride 0.2% ophthalmic solution suppressed histamine-induced wheals and flares on skin-prick testing. A randomized, double-blinded, placebo-controlled, single-center, cross-over pilot study was performed that compared histamine-induced wheal and flare areas after 7-10 days of treatment with both olopatadine 0.2% ophthalmic solution and artificial tears, allowing for a 7- to 10-day washout period between medications. From a total of 24 patients randomized, 21 subjects completed the study, 86% of whom were female. There were no statistically significant differences among both the wheal and the flare areas when comparing treatment with olopatadine and placebo, under the 5% significance level. Although characterized by a small sample size and a preponderance of female subjects, our data suggest that olopatadine does not suppress wheal and flare areas during allergy testing, and discontinuation in preparation for skin-prick testing does not appear to be necessary.

AB - The significant morbidity of allergic rhinitis and allergic conjunctivitis necessitates that diagnosis must be as accurate as possible. However, the very drugs used to treat allergic symptoms have been found to suppress histamine-induced skin testing, making the diagnosis very challenging. Oral formulations of antihistamines are well known to diminish skin test reactivity, but ocular application has never been studied to our knowledge. This study was performed to evaluate whether olopatadine hydrochloride 0.2% ophthalmic solution suppressed histamine-induced wheals and flares on skin-prick testing. A randomized, double-blinded, placebo-controlled, single-center, cross-over pilot study was performed that compared histamine-induced wheal and flare areas after 7-10 days of treatment with both olopatadine 0.2% ophthalmic solution and artificial tears, allowing for a 7- to 10-day washout period between medications. From a total of 24 patients randomized, 21 subjects completed the study, 86% of whom were female. There were no statistically significant differences among both the wheal and the flare areas when comparing treatment with olopatadine and placebo, under the 5% significance level. Although characterized by a small sample size and a preponderance of female subjects, our data suggest that olopatadine does not suppress wheal and flare areas during allergy testing, and discontinuation in preparation for skin-prick testing does not appear to be necessary.

KW - Allergic rhinitis

KW - Allergy

KW - Azelastine

KW - Conjunctivitis

KW - Flare

KW - Histamine

KW - Olopatadine

KW - Skin prick

KW - Skin testing

KW - Wheal

UR - http://www.scopus.com/inward/record.url?scp=61749103050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61749103050&partnerID=8YFLogxK

U2 - 10.2500/aap.2008.29.3173

DO - 10.2500/aap.2008.29.3173

M3 - Article

C2 - 19173791

AN - SCOPUS:61749103050

VL - 29

SP - 636

EP - 639

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 6

ER -